Amgen (NASDAQ:AMGN) presented Phase III data at the European Society for Medical Oncology Congress 2026 showing that its DLL3-targeting BiTE therapy IMDELLTRA, when added to durvalumab maintenance treatment, improved survival outcomes for patients with extensive-stage small-cell lung cancer whose disease had not progressed after initial chemoimmunotherapy. The DeLLphi-305 study compared IMDELLTRA plus AstraZeneca’s IMFINZI, or […]